Denais et al. discovered a novel secretion pathway protein, Golm1, that interacts with dymeclin to influence endochondral bone formation and Shen et al. found that Golm1 could promote osteoporosis through inhibition of the osteogenic differentiation of BMSCs (40, 41). Here, DYM is linked to osteoporosis.